Monday , December 18 2017
Home / Therapies / SGLT-2 Therapy Center (page 14)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

New Guideline Released on Pharmacological Management of Obesity

The Endocrine Society has released a clinical practice guideline on the pharmacological management of obesity that includes recommendations on strategies for prescribing weight loss drugs… During a recent press conference, Caroline Apovian, MD, of Boston University, the lead author of the new guideline, “This is really the first guideline of …

Read More »

FDA Approves Xigduo XR, a New Dapagliflozin-Metformin Combination

The once-daily oral tablet is the first in the U.S. to combine the SGLT-2 inhibitor dapagliflozin with the biguanide extended-release (XR) metformin hydrochloride.. The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with …

Read More »